EMA approves new European pfizer vaccine production sites
The European Medicines Agency (EMA) has approved new production sites for pfizer/BioNTech’s coronavirus vaccine. Thanks to that step, many more vaccines can be made in the European Union this year, the regulator reports.
The medicines authority agrees to the production of Comirnaty, as the vaccine developed by Pfizer and BioNTech is called, in the French town of Saint-Rémy-sur-Avre.
This will result in an additional 51 million doses of the drug this year. The facility is used by the French pharmaceutical company Delpharm, which often produces medicines or vaccines on behalf of other companies.
The EMA has also approved a BioNTech production site in Marburg, Germany. This is where the active substance of the corona vaccines is produced. As a result, about 410 million more doses can be made this year.
The European drug watchdog further approved a U.S. manufacturing facility in Indiana for making Moderna vaccines. Pharmaceutical company Catalent makes the vaccines on behalf of Moderna. The EMA also approved several locations where Catalent packages the vaccines and monitors the quality.